Puma Biotechnology (PBYI) Gains from Investment Securities (2011 - 2026)

Puma Biotechnology has reported Gains from Investment Securities for 16 years, with the latest figure at -$6000.0 in Q1 2026.

• For the quarter ending Q1 2026, Gains from Investment Securities fell 100.14% year-over-year to -$6000.0; the trailing twelve-month figure through Mar 2026 stood at -$6000.0 (down 100.14% YoY), and the FY2025 full-year result was $3.2 million, down 20.6% from the prior year.
• Gains from Investment Securities for Q1 2026 stood at -$6000.0, down from $1.4 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $4.4 million in Q1 2025, with the low at -$6000.0 in Q1 2026.
• Historically, Gains from Investment Securities has averaged $883642.1 across 5 years, with a median of $531983.5 in 2022.
• Annual changes were most pronounced in 2022 — Gains from Investment Securities soared 58335.3% — and 2026, when it plunged 100.14%.
• Puma Biotechnology's Gains from Investment Securities stood at $582353.0 in 2022, then declined by 0.13% to $581614.0 in 2023, then declined by 24.1% to $441430.0 in 2024, then jumped by 218.53% to $1.4 million in 2025, then slumped by 100.43% to -$6000.0 in 2026.
• The last three Gains from Investment Securities figures came in at -$6000.0 (Q1 2026), $1.4 million (Q3 2025), and $1.1 million (Q2 2025), per Business Quant data.